Pembrolizumab versus paclitaxel for previously treated advanced gastric or gastroesophageal junction cancer (KEYNOTE-063): A randomized, open-label, phase 3 trial in Asian patients
Background KEYNOTE-063 (NCT03019588) investigated pembrolizumab versus paclitaxel as second-line therapy in Asian patients with advanced programmed death ligand 1 (PD-L1)-positive (combined positive score >= 1) gastric/gastroesophageal junction (GEJ) cancer. Methods This randomized, open-label, p...
Saved in:
Main Authors: | , , , , , , , , , , , , , , , , , , , |
---|---|
Format: | Article |
Published: |
Wiley
2022
|
Subjects: | |
Online Access: | http://eprints.um.edu.my/33657/ |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Institution: | Universiti Malaya |